To a solution of 3,5-dichloropyridine 1b–c or 1f (0.484 mmol), 3,4,5-trimethoxyphenylboronic acid (2) (103 mg, 0.484 mmol), and XPhos Pd G2 (19 mg, 0.024 mmol) in butanol (3 mL) at room temperature was added K3PO4 (1.3 M solution in water) (0.748 mL, 0.973 mmol). ...
ALKgene rearrangement was observed in 3%–5% of non-small cell lung cancer patients, and multiple ALK-tyrosine kinase inhibitors (TKIs) have been sequentially used. Multiple ALK-TKI resistance mutations have been identified from the patients, and several compound mutations, such as I1171N + ...